Search Results
UMR9019, Genome Integrity and Cancers, CNRS, Villejuif, France
Search for other papers by Camille Buffet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
CHU Nantes/ICO, Saint-Herblain, France
Search for other papers by Françoise Kraeber-Bodéré in
Google Scholar
PubMed
CHU Nantes/ICO, Saint-Herblain, France
Search for other papers by Caroline Bodet-Milin in
Google Scholar
PubMed
Université de Paris, Paris, France
Search for other papers by Laure Cabanes in
Google Scholar
PubMed
Department of Radiology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Anthony Dohan in
Google Scholar
PubMed
Search for other papers by Pascal Leprince in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute, Villejuif, France
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Department of Medical Oncology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Olivier Huillard in
Google Scholar
PubMed
Université de Paris, Paris, France
Department of Endocrinology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Lionel Groussin in
Google Scholar
PubMed
Background: Cardiac metastases from thyroid cancers are uncommon with a poor prognosis. There is a lack of long-term follow-up studies. Cases: We report 2 cases of cardiac metastasis from medullary thyroid cancer (MTC). Both patients presented limited metastatic disease apart from a cardiac metastasis. The initial diagnosis was challenging and was facilitated by functional imaging with an immuno-PET-CT using an anti-CEA bispecific antibody and a <sup>68</sup>Ga-labeled peptide. Both patients were treated with the multitarget kinase inhibitor vandetanib with prolonged stability. The first patient was alive at the last follow-up, 14 years after the diagnosis of cardiac metastasis. The second patient required surgical excision of the cardiac mass because of disease progression under vandetanib. Conclusion: These cases illustrate long-term survival and effectiveness of clinical management of 2 patients who developed cardiac metastases from MTC, in the current era of personalized medicine with targeted therapy.
Search for other papers by Furio Pacini in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Daria Handkiewicz-Junak in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Johannes W Smit in
Google Scholar
PubMed
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients’ risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Constance Xhaard in
Google Scholar
PubMed
Search for other papers by Juan J. Lence-Anta in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Yan Ren in
Google Scholar
PubMed
Rhône-Alpes Thyroid Cancer Registry, Cancer Research Center of Lyon (UMR INSERM 1052, CNRS 5286), RTH Laennec Faculty of Medicine, University of Lyon, Lyon
Search for other papers by Françoise Borson-Chazot in
Google Scholar
PubMed
Search for other papers by Geneviève Sassolas in
Google Scholar
PubMed
Search for other papers by Claire Schvartz in
Google Scholar
PubMed
Search for other papers by Marc Colonna in
Google Scholar
PubMed
French National Registry of Childhood Solid Tumours, CHU, Nancy
Search for other papers by Brigitte Lacour in
Google Scholar
PubMed
Search for other papers by Arlette Danzon in
Google Scholar
PubMed
Search for other papers by Michel Velten in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Enora Clero in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Stéphane Maillard in
Google Scholar
PubMed
Search for other papers by Emilie Marrer in
Google Scholar
PubMed
Search for other papers by Laurent Bailly in
Google Scholar
PubMed
Search for other papers by Eugènia Mariné Barjoan in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Jacques Orgiazzi in
Google Scholar
PubMed
Université Paris-Saclay, Villejuif, France
Search for other papers by Elisabeth Adjadj in
Google Scholar
PubMed
Search for other papers by Celia M. Pereda in
Google Scholar
PubMed
Search for other papers by Silvia Turcios in
Google Scholar
PubMed
Search for other papers by Milagros Velasco in
Google Scholar
PubMed
Search for other papers by Mae Chappe in
Google Scholar
PubMed
Search for other papers by Idalmis Infante in
Google Scholar
PubMed
Search for other papers by Marlene Bustillo in
Google Scholar
PubMed
Search for other papers by Anabel García in
Google Scholar
PubMed
Search for other papers by Sirced Salazar in
Google Scholar
PubMed
Search for other papers by Regla Rodriguez in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Mohamed Amine Benadjaoud in
Google Scholar
PubMed
Search for other papers by Rosa M. Ortiz in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Carole Rubino in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Florent de Vathaire in
Google Scholar
PubMed
Purpose: Physical activity has been hypothesized to influence cancer occurrence through several mechanisms. To date, its relation with thyroid cancer risk has been examined in relatively few studies. We pooled 2 case-control studies conducted in Cuba and Eastern France to assess the relationship between self-reported practice of recreational physical activity since childhood and thyroid cancer risk. Methods: This pooled study included 1,008 cases of differentiated thyroid cancer (DTC) matched with 1,088 controls (age range 9-35 and 17-60 years in the French and Cuban studies, respectively). Risk factors associated with the practice of recreational physical activity were estimated using OR and 95% CI. Logistic regressions were stratified by age class, country, and gender and were adjusted for ethnic group, level of education, number of pregnancies for women, height, BMI, and smoking status. Results: Overall, the risk of thyroid cancer was slightly reduced among subjects who reported recreational physical activity (OR = 0.8; 95% CI 0.5-1.0). The weekly frequency (i.e. h/week) seems to be more relevant than the duration (years). Conclusion: Long-term recreational physical activity, practiced since childhood, may reduce the DTC risk. However, the mechanisms whereby the DTC risk decreases are not yet entirely clear.
